In focus · trending topic

DMD

26 stories · following the connections

Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress

By Nasdaq OMXMar 29, 2017, 11:02 AM UTC

Summit to Extend Ongoing PhaseOut DMD Clinical Trial of Ezutromid in Patients With DMD

By Nasdaq OMXMar 27, 2017, 11:02 AM UTC

Summit Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference

By Nasdaq OMXMar 15, 2017, 11:00 AM UTC

FibroGen Reports Fiscal 2016 Financial Results

By Nasdaq OMXMar 1, 2017, 9:03 PM UTC

FibroGen Reports Fiscal 2016 Financial Results

By Nasdaq OMXMar 1, 2017, 9:03 PM UTC

Summit Therapeutics Recognises 10th Annual Rare Disease Day

By Nasdaq OMXFeb 28, 2017, 12:00 PM UTC

Summit Therapeutics to Participate in February Investor Conferences

By Nasdaq OMXFeb 2, 2017, 12:00 PM UTC

Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy

By Nasdaq OMXSep 27, 2016, 11:00 AM UTC